| Verastem is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and life of cancer patients. Co.'s marketed product, COPIKTRA® (duvelisib) capsules, and primary product candidates, defactinib and CH5126766, utilize a multi-faceted approach designed to treat cancers originating either in the blood or major organ systems. Co. is developing duvelisib and its product candidates in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, colorectal cancer and pancreatic cancer. Co. is also developing duvelisib for the treatment of patients with peripheral T-cell lymphoma. We show 38 historical shares outstanding datapoints in our coverage of VSTM's shares outstanding history.|
Understanding the changing numbers of VSTM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VSTM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VSTM by allowing them to research VSTM shares outstanding history
as well as any other stock in our coverage universe.